NCT06545877

Brief Summary

This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
38mo left

Started Sep 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress54%
Sep 2022Jun 2029

Study Start

First participant enrolled

September 16, 2022

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

August 6, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 9, 2024

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2026

Completed
3.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 22, 2029

Expected
Last Updated

August 20, 2025

Status Verified

August 1, 2025

Enrollment Period

3.5 years

First QC Date

August 6, 2024

Last Update Submit

August 14, 2025

Conditions

Infertility

Outcome Measures

Primary Outcomes (1)

  • Adverse Events

    Frequency of Adverse Events

    From initiation of the administration, in case of embryo transfer is not performed, until 1 week after oocyte collection, and in case embryo transfer is performed, 6 weeks after embryo transfer

Eligibility Criteria

Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women who are undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

You may qualify if:

  • Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ferring Investigational Site

Omitama, Ibaraki, Japan

RECRUITING

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Study Officials

  • Global Clinical Compliance

    Ferring Pharmaceuticals

    STUDY DIRECTOR

Central Study Contacts

Global Clinical Compliance

CONTACT

+1 833-548-1402 (US/Canada)DK0-Disclosure@ferring.com

Global Clinical Compliance

CONTACT

+1 862-286-5200 (outside US)DK0-Disclosure@ferring.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 6, 2024

First Posted

August 9, 2024

Study Start

September 16, 2022

Primary Completion

February 28, 2026

Study Completion (Estimated)

June 22, 2029

Last Updated

August 20, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations

JP(1)